May 17, 2024
BRCA is no longer the only gene that identifies hereditary breast cancer (BC) syndromes. Pathogenic variants of CDH1 identify a form of hereditary lobular BC (HLBC) […]
May 17, 2024
A relatively high percentage of men in their 70s and 80s, as well those determined to have a limited life expectancy, report receiving prostate cancer screening, […]
May 17, 2024
A major trial has demonstrated that low risk prostate cancers do not fare better by adding 6 months of hormone treatment to radiotherapy following radical prostatectomy, […]
May 17, 2024
TOPLINE: A minority of patients with metastatic castration-resistant prostate cancer (mCRPC) in the United States undergo genetic testing for homologous recombination repair (HRR) mutations, despite the […]
May 16, 2024
The US Food and Drug Administration has granted accelerated approval to tarlatamab-dlle (Imdelltra, Amgen) for extensive-stage small cell lung cancer (SCLC) with disease progression on or […]
May 16, 2024
Adding atezolizumab to chemotherapy in patients with anti–programmed death ligand 1 (PD-L1)–positive triple-negative breast cancer (TNBC) who have relapsed within 12 months of their last curative […]
May 16, 2024
TOPLINE: In patients with localized pancreatic ductal adenocarcinoma (PDAC), failure to undergo resection following neoadjuvant chemotherapy is common and associated with worse survival. Researchers identified few […]
May 16, 2024
The US Food and Drug Administration has granted accelerated approval to lisocabtagene maraleucel (Breyanzi, Juno Therapeutics /Bristol Myers Squibb) for adults with relapsed or refractory follicular […]
May 15, 2024
While major guidelines support mammography for routine breast cancer screening in average-risk women, the decision to offer additional screening and which supplemental tool to use can […]